5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts

Page 5 of 5

01. Vaxart, Inc. (NASDAQ:VXRT)

Price Reaction after the Upgrade: +0.2000 (+20.40%)

On January 31, B.Riley analyst Mayank Mamtani made a significant adjustment within the pharmaceutical industry by upgrading Vaxart, Inc. (NASDAQ:VXRT) shares. Mamtani raised Vaxart, Inc. (NASDAQ:VXRT) rating from Neutral to Buy, indicating a shift in perception regarding the company’s performance and potential within the healthcare sector. Following the upgrade, Vaxart, Inc. (NASDAQ:VXRT) witnessed a notable increase of 20.40% in its market price on the closing bell of January 31, reaching $1.18. This substantial surge in market price reflects a positive market response to Mamtani’s upgraded outlook for Vaxart Inc., suggesting heightened investor confidence in the company’s trajectory. The upgraded rating implies that B.Riley perceives Vaxart Inc. as undervalued and believes that it has the potential for significant growth in the foreseeable future. Overall, Mamtani’s upgrade of Vaxart, Inc. (NASDAQ:VXRT) underscores the company’s potential to make strides in the pharmaceutical industry. Despite the short-term market price increase, Mamtani’s analysis suggests that Vaxart Inc. is well-positioned to capitalize on opportunities in the healthcare sector and deliver long-term value to shareholders.

You can also take a peek at 20 Most Popular RTDs in America and 15 Cities Where You Can Buy a Home for Under 300k.

Page 5 of 5